Femasys stock.

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional …

Femasys stock. Things To Know About Femasys stock.

Dec 1, 2023 · Femasys (FEMY) stock price is up 1,250% but there are 2 key risks. The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar... 7 weeks ago - Invezz. Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position. The Fly 12 days ago. Track Femasys Inc (FEMY) Stock Price, Quote, latest community messages, …WebRTTNews. Nov. 15, 2023, 08:41 AM. (RTTNews) - PharmaCyte Biotech, Inc. (PMCB) has made a $5 million investment in Femasys, Inc. (FEMY), a biomedical company. Femasys offers a broad portfolio of in ...News All Videos Press Releases Conversation Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer -- Thought leader from top …Web

Jul 27, 2023 · FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ ...

Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.

Nov 30, 2023 · Why Is Femasys (FEMY) Stock Up 181% Today? investorplace.com - September 26 at 9:11 AM. Femasys up 205% as FDA clears fertility treatment. seekingalpha.com - September 25 at 11:56 PM. Femasys Secures FDA 510 (k) Clearance To Market FemaSeed. markets.businessinsider.com - September 25 at 6:56 PM. Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late ...Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testing

Oct 4, 2023 · Publish : 04 Oct 2023, 07:17 PM Update : 04 Oct 2023, 07:17 PM. Femasys (NASDAQ: FEMY) stock is down 50% over night from highs. A reasonable bet would be that FEMY stock will continue to fall back to more reasonable levels. For, as far as we can see at least, this is a flurry of speculation producing far too much movement for the objective ...

Femasys Inc. announced that it has entered into a Securities Purchase Agreement with new lead investor PharmaCyte Biotech, Inc. to issue 6% senior unsecured convertible notes for the gross proceeds...

Under the terms of the investment, the investors were also issued two series of warrants: warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per share expiring one year from issuance and warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.475 per …Femasys (FEMY) shares fell 13% premarket on Wednesday after the biomedical company announced an offering to raise $3.9M.The company is selling 3,196,722 shares of common stock (or...Femasys Inc (FEMY) stock is trading at $1.10 as of 10:08 AM on Wednesday, Nov 15, an increase of $0.17, or 18.28% from the previous closing price of $0.93. The stock has traded between $1.05 and $1.25 so far today. Volume today is 2,748,419 compared to average volume of 3,456,068.FEMY Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $10.67 with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 620.95% change from the last price of $1.48.Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWebFemasys Inc ( FEMY) has fallen Tuesday morning, with the stock losing -1.54% in pre-market trading to 1.28. FEMY's short-term technical score of 47 indicates that the stock has traded less bullishly over the last month than 53% of stocks on the market. In the Medical Instruments & Supplies industry, which ranks 80 out of 146 industries, …Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.

146.71. +1.95%. 45.70M. View today's Femasys Inc stock price and latest FEMY news and analysis. Create real-time notifications to follow any changes in the live stock price.WebFemasys saw a decline in short interest in November. As of November 15th, there was short interest totaling 286,700 shares, a decline of 33.0% from the previous total of 427,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will ...Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late ...Femasys (FEMY) For the next stock on our list, we’ll take a look at another company in the health care universe. Femasys occupies a unique niche, whose nature is implied in the name.Institutional Ownership and Shareholders. Femasys Inc (US:FEMY) has 32 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,650,299 shares. Largest shareholders include Clear Street Llc, Clear Creek Financial Management, LLC, Bank Of America ...RTTNews. Nov. 15, 2023, 08:41 AM. (RTTNews) - PharmaCyte Biotech, Inc. (PMCB) has made a $5 million investment in Femasys, Inc. (FEMY), a biomedical company. Femasys offers a broad portfolio of in ...

Nov 18, 2023 · Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81. Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.

Track Femasys Inc (FEMY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Comparatively, 16.4% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Earnings & Valuation. This table compares Beyond Air and Femasys’ revenue, earnings per share …News All Videos Press Releases Conversation Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer -- Thought leader from top …WebInvesting in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Publish : 04 Oct 2023, 07:17 PM Update : 04 Oct 2023, 07:17 PM. Femasys (NASDAQ: FEMY) stock is down 50% over night from highs. A reasonable bet would be that FEMY stock will continue to fall back to more reasonable levels. For, as far as we can see at least, this is a flurry of speculation producing far too much movement for the objective ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Femasys, a medical device company, ... Its stock ran from $0.33 to an intraday high of $4.75 a few days later, only to fall back to the $1 range. During that flurry of activity, ...Based on short-term price targets offered by three analysts, the average price target for Femasys Inc. comes to $9.00. The forecasts range from a low of $5.00 to a high of $12.00. The average ...Oct 24, 2023 · Femasys is a commercial-stage company with four approved products — FemaSeed (intratubal Insemination), FemVue (contrast generating device), FemCath (selective delivery catheter) and FemCerv ... About Femasys Inc · Most Popular · Stocks Rankings for FEMY · Femasys Inc Vitals · Femasys Inc Competitors - Telecommunications Equipment · Top Movers Daily change%.

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWeb

In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.

Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility. Find real-time FEMY - Femasys Inc stock quotes, company profile, news and forecasts from CNN Business.Apr 19, 2023 · In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions. FEMY Femasys Bull Pennant On 7/13/2021 Jonestrading brokerage Initiated Coverage with a Buy rating and a $8.45 Price Target On 7/13/2021 Chardan Capital brokerage Initiated Coverage with a Buy rating and a $25.00 Price Target How do you explain such a big difference in valuation?Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide …WebNov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ... Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.ACADIA Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACADIA’s stock has increased 40.1% year to date. It beat earnings estimates in two of the last four quarters while ...John Dyett has not been actively trading shares of Femasys over the course of the past ninety days. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.

Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.Since then, however, the stock has slipped by 47%. Writing on Femasys for Chardan Research, 5-star analyst Keay Nakae takes care to laud “the potential of its next generation products addressing ...What is the target price for Femasys (FEMY) stock? The latest price target for Femasys ( NASDAQ: FEMY) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a ...Dec 1, 2023 · Grading Femasys Inc Stock. Before you choose to buy, sell or hold Femasys Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. Instagram:https://instagram. klaviyo iponyse nsclincoln pennies 2009is groundfloor a good investment Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.About Femasys Inc · Most Popular · Stocks Rankings for FEMY · Femasys Inc Vitals · Femasys Inc Competitors - Telecommunications Equipment · Top Movers Daily change%. us treasury 3 month ratelouis navellier portfolio grader Aug 10, 2023 · Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. August 10, 2023 08:00 ET ... Common stock, $.001 par, 200,000,000 authorized, ... Sep 25, 2023 · Femasys’ FemBloc ® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for ... tu simple stock John Dyett has not been actively trading shares of Femasys over the course of the past ninety days. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.Femasys’ FemaSeed ® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared (and also approved in Canada). The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada and ...At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.